Long-Term Results of Bioresorbable Vascular Scaffolds in Patients With In-Stent Restenosis: The RIBS VI Study.
JACC Cardiovasc Interv
; 17(15): 1825-1836, 2024 Aug 12.
Article
em En
| MEDLINE
| ID: mdl-39142758
ABSTRACT
BACKGROUND:
In patients with in-stent restenosis (ISR) bioresorbable vascular scaffolds (BVS) provide similar results to drug-coated balloons (DCBs) but are inferior to drug-eluting stents (DES) at 1 year. However, the long-term efficacy of BVS in these patients remains unknown.OBJECTIVES:
This study sought to assess the long-term safety and efficacy of BVS in patients with ISR.METHODS:
RIBS VI (Restenosis Intrastent Bioresorbable Vascular Scaffolds Treatment; NCT02672878) and RIBS VI Scoring (Restenosis Intrastent Bioresorbable Vascular Scaffolds Treatment With Scoring Balloon; NTC03069066) are prospective multicenter studies designed to evaluate the results of BVS in patients with ISR (N = 220). The inclusion and exclusion criteria were identical to those used in the RIBS IV (ISR of DES) (Restenosis Intra-stent of Drug-eluting Stents Drug-eluting Balloon vs Everolimus-eluting Stent; NCT01239940) and RIBS V (ISR of bare-metal stents) (Restenosis Intra-stent of Bare Metal Stents Paclitaxel-eluting Balloon vs Everolimus-eluting Stent; NCT01239953) randomized trials (including 249 ISR patients treated with DCBs and 249 ISR patients treated with DES). A prespecified comparison of the long-term results obtained with these treatment modalities (ie, DES, DCBs, and BVS) was performed.RESULTS:
Clinical follow-up at 3 years was obtained in all (100%) 718 patients. The 3-year target lesion revascularization rate after BVS was 14.1% (vs 12.9% after DCBs [not significant], and 5.2% after DES [HR 2.80; 95% CI 1.47-5.36; P = 0.001]). In a landmark analysis (>1 year), the target lesion revascularization rate after BVS was higher than after DES (adjusted HR 3.41; 95% CI 1.15-10.08) and DCBs (adjusted HR 3.33; 95% CI 1.14-9.70). Very late vessel thrombosis was also more frequent with BVS (BVS 1.8%, DCBs 0.4%, DES 0%; P = 0.03).CONCLUSIONS:
In patients with ISR, late clinical results of DES are superior to those obtained with DCBs and BVS. Beyond the first year, DCBs are safer and more effective than BVS.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Desenho de Prótese
/
Implantes Absorvíveis
/
Reestenose Coronária
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article